NEW YORK, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of investors who purchased Atossa Genetics, Inc. ("Atossa" or the "Company") (Nasdaq:ATOS) stock between November 8, 2012 and October 4, 2013.
For more information, click here: http://zlk.9nl.com/atossa-genetics-atos.
The Complaint alleges that throughout the Class Period defendants made false and misleading statements and/or failed to disclose the following: a) that the Company failed to submit an additional 510(k) notification to obtain necessary FDA clearance as it made material changes to the Nipple Aspirate Fluid specimen collection process; b) that the Company improperly marketed its device by using certain promotional claims to market its ForeCYTE Breast Health Test and the MASCT device; and c) that the Company was in violation of FDA Good Manufacturing Practices regulations.
On October 4, 2013, Atossa announced a voluntary recall of its ForeCYTE Test, including a recall of the MASCT System Kit and Patient Sample Kit. The recall commenced to address concerns raised in a February 2013 warning letter issued by the U.S. Food and Drug Administration.
If you suffered a loss in Atossa you have until December 9, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/atossa-genetics-atos.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.